Osteoporosis Musculoskeletal Diseases Osteoporosis in diseases classified elsewhere
Conditions
Interventions
Participants were stratified by sex and randomly assigned to receive a calcium supplement or placebo. The randomisation procedure was conducted by a member of staff in Cambridge UK who was not involve
Shire Pharmaceuticals Ltd, Andover, UK and Nycomed Pharma AS, Oslo) containing 500 mg elemental calcium/tablet. The placebo consisted of similar tablets, produced by the manufacturer of the calcium ta
Sponsors
MRC Human Nutrition Research (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Children aged 8-12 years old living in the rural village of Keneba, West Kiang, The Gambia. 2. Healthy, with no history of any medical condition known to affect calcium or bone metabolism 3. No recent fracture 4. Non-consumer of alcohol, antacids, calcium or other nutritional supplements 5. Non-smokers 6. Girls not on contraceptive pills
Exclusion criteria
Exclusion criteria: Does not meet inclusion criteria
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Bone mineral status measures [initially forearm single photon absorptiometry (SPA), then whole-body and regional dual energy X-ray absorptiometry (DXA)] at 0, 12, 24, 36 months and regular intervals to adulthood 2. Anthropometry (height, weight, mid upper arm circumference, triceps skinfold) at 0, 12, 24, 36 months and regular intervals to adulthood | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Biochemical markers of calcium and bone metabolism measured in blood and urine at 0, 12, 24, 36 months and regular intervals to adulthood 2. Body composition measures (whole-body DXA) from 36 months to adulthood 3. Radial and tibial bone and muscle measures by peripheral quantitative computed tomography (pQCT) in early aldulthood | — |
Countries
Gambia
Outcome results
None listed